|
|
|
|
| LEADER |
01000caa a22002652c 4500 |
| 001 |
NLM352308036 |
| 003 |
DE-627 |
| 005 |
20250304091219.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231226s2023 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1016/j.clim.2023.109248
|2 doi
|
| 028 |
5 |
2 |
|a pubmed25n1174.xml
|
| 035 |
|
|
|a (DE-627)NLM352308036
|
| 035 |
|
|
|a (NLM)36720440
|
| 035 |
|
|
|a (PII)S1521-6616(23)00027-X
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Törnell, Andreas
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Induction and subsequent decline of S1-specific T cell reactivity after COVID-19 vaccination
|
| 264 |
|
1 |
|c 2023
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 14.03.2023
|
| 500 |
|
|
|a Date Revised 18.03.2023
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved.
|
| 520 |
|
|
|a We analyzed magnitude and duration of SARS-CoV-2-specific T cell responses in healthy, infection-naïve subjects receiving COVID-19 vaccines. Overlapping peptides spanning the N-terminal spike 1 (S1) domain of the spike protein triggered secretion of the T cell-derived cytokine interleukin-2 ex vivo in 94/94 whole blood samples from vaccinated subjects at levels exceeding those recorded in all 45 pre-vaccination samples. S1-specific T cell reactivity was stronger in vaccinated subjects compared with subjects recovering from natural COVID-19 and decayed with an estimated half-life of 134 days in the first six months after the 2nd vaccination. We conclude that COVID-19 vaccination induces robust T cell immunity that subsequently declines. EudraCT 2021-000349-42. https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000349-42
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Research Support, Non-U.S. Gov't
|
| 650 |
|
4 |
|a COVID-19
|
| 650 |
|
4 |
|a Longevity
|
| 650 |
|
4 |
|a SARS-CoV-2
|
| 650 |
|
4 |
|a T cells
|
| 650 |
|
4 |
|a Vaccine
|
| 650 |
|
7 |
|a COVID-19 Vaccines
|2 NLM
|
| 650 |
|
7 |
|a Antibodies, Viral
|2 NLM
|
| 700 |
1 |
|
|a Grauers Wiktorin, Hanna
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Ringlander, Johan
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Arabpour, Mohammad
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Nilsson, Staffan
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Lindh, Magnus
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Lagging, Martin
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Hellstrand, Kristoffer
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Martner, Anna
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 248(2023) vom: 01. März, Seite 109248
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnas
|
| 773 |
1 |
8 |
|g volume:248
|g year:2023
|g day:01
|g month:03
|g pages:109248
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1016/j.clim.2023.109248
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 248
|j 2023
|b 01
|c 03
|h 109248
|